allotment, page-17

Reading a few articles this afternoon, it seems that the big pharmas are somewhat hesitant to snap up idenix or achillion because their lead drug is a protease inhibitor which most of the pharmas already have in abundance and dont require to supplement their cocktail of anti virals.

I believe wednesday's presentation by biotron at the JP Morgan conference in San Fran will be a pivotal moment for the company.

In the current euphoria about hepatiis C, Biotron has never been in a better commercial position having $9 million in the bank, positive phase 2a HCV results, future HIV results and a new novel compound that targets the p7 protein in the HCV virus and viropirin in the HIV.

If I was a company pharma executive and I'm trying to impress my board and shareholders, acquiring a bio drug developer that has a new way to tackle HCV/HIV without paying the billion dollar plus figures of Pharmasset and Inhibitex, it looks like a win win for all.

I have a strong feeling a commercial offer will be made within 2 weeks. Based on the premiums others are achieving, any offer would have to be over 60 cents to gain shareholder approval.

Very exciting times, Im all in today.